Efficacy and Safety Study of Oncolytic Virus (OH2) Intratumoral Injection in Locally Advanced or Metastatic Bladder Cancer a Phase Ⅱ Clinical Trial
Latest Information Update: 14 Aug 2024
At a glance
- Drugs OH 2 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Binhui Biopharmaceutical
- 12 Aug 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 12 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 27 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.